查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2044502

非小細胞肺癌：全球市場展望、流行病學、競爭格局和市場預測報告（32個主要市場），2025-2035年

Global Non-Small Cell Lung Cancer - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 157 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 法國非小細胞肺癌 (NSCLC) 市場預計將從 2025 年的 13 億美元成長到 2035 年的 32 億美元，這表明在癌症治療創新的推動下，市場正在強勁擴張。
  • 推動市場成長的因素如下：
  • 高價分子標靶療法和免疫療法的應用日益增加。
  • 擴大基於生物標記的治療合格，並推廣個人化醫療方法
  • 生存率的提高導致治療週期延長。
  • 市場規模的成長得益於新一代抗癌藥物的不斷推出和聯合療法的日益普及。
  • 一系列強大的新型分子標靶療法、抗體藥物複合體(ADC) 和下一代查核點抑制劑有望帶來巨大的商業性機會。
  • 未來的成長取決於早期檢測的進展、克服治療抗藥性的進展以及提高進行性和轉移性非小細胞肺癌 (NSCLC) 患者的長期存活率。

非小細胞肺癌概述

非小細胞肺癌（NSCLC）是最常見的肺癌類型，包括腺癌、鱗狀細胞癌和大細胞癌。多種致癌突變參與其發生髮展，包括EGFR突變、ALK和ROS1重排、KRAS G12C突變、MET外顯子14跳躍突變、RET融合突變、BRAF V600E致癌性以及PD-L1過度表現。吸菸仍然是主要的危險因素，但攜帶可治療標靶驅動基因突變的非吸菸者腺癌病例正在增加。患者通常表現為持續性咳嗽、咳血、呼吸困難和全身症狀，且確診時往往已晚期。全面的次世代定序和PD-L1免疫組化檢測對於診斷至關重要。對於PD-L1高表達的患者，Pembrolizumab單藥治療是標準治療方案；而對於PD-L1低表達的患者，則採用化療合併免疫療法。對於EGFR突變患者，可採用Osimertinib藥物治療或聯合治療。尤其值得一提的是，近期核准的皮下製劑與單藥治療相比，在無惡化生存期（PFS）方面表現出顯著優勢，從根本上重新定義了一線治療的標準。Alectinib用於ALK突變，恩曲替尼用於ROS1突變，阿達格拉西布用於KRAS G12C突變，替泊替尼用於MET突變，塞帕替尼用於RET突變，Dabrafenib/Trametinib用於BRAF V600E突變。對於局限性疾病，手術切除仍是根治性治療方法；對於EGFR突變陽性的非小細胞肺癌患者，術後輔助性治療Osimertinib提高存活率。預後因疾病分期和分子亞型而異。多學科管理、戒菸和以患者為中心的輔助治療對於最佳化治療效果至關重要。

主要亮點

  • 在德國，經生存已調整的的非小細胞肺癌 (NSCLC) 盛行率預計將從 2025 年的 497,473 例增加到 2035 年的 532,039 例，這反映了生存結果的改善和疾病負擔的加重。
  • 非小細胞肺癌仍然是最常見的肺癌亞型，佔全球肺癌診斷和死亡病例的大多數。
  • 隨著分子診斷和生物標記檢測技術的日益普及，精準腫瘤學方法在德國的應用也越來越廣泛。
  • 治療模式已顯著轉向標靶治療和免疫腫瘤藥物，從而提高了無惡化生存期和總存活期。
  • 在抗藥性突變、晚期診斷、轉移性疾病進展和治療順序最佳化方面仍存在未滿足的需求。
  • 隨著對標靶 KRAS、EGFR、ALK、HER2 和 PD-(L)1的治療方法的關注度不斷提高，預計在預測期內競爭格局將進一步發生變化。

市場定義：

  • 北美洲（美國、加拿大）
  • 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
  • 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
  • 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
  • 非洲（埃及、奈及利亞、南非、摩洛哥）
  • 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

格式化和更新訊息

  • 詳細報告（PDF）
  • 市場預測模型（基於微軟Excel）
  • 流行病學數據（MS Excel，互動式工具）
  • 高階主管洞察（PPT簡報）
  • 其他功能：定期更新、自訂和顧問支援。
  • 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

  • 我們如何最佳化在 32 個市場（北美、歐洲、中東、亞太、非洲和南美/拉丁美洲）的藥物開發和生命週期管理策略？
  • 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
  • 未來十年市場收入和病患佔有率的預測是多少？
  • 哪些因素對市場趨勢影響最大？
  • 受訪專家對目前和新興的治療方法有何看法？
  • 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
  • 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
  • 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

  • 北美洲（美國、加拿大）
  • 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
  • 中東

大公司

  • Pfizer
  • Merck Sharp &Dohme LLC
  • AstraZeneca
  • GlaxoSmithKline
  • BeiGene
  • Arcus Biosciences, Inc.
  • AbbVie
  • STCube, Inc.
  • Avistone Biotechnology Co., Ltd.
  • Regeneron Pharmaceuticals
  • Suzhou Zelgen Biopharmaceuticals Co., Ltd.
  • Daiichi Sankyo
  • Akeso
  • Bristol-Myers Squibb
  • RemeGen Co., Ltd.
  • BioNTech SE
  • Hoffmann-La Roche
  • Nuvation Bio Inc.
  • TJ Biopharma Co., Ltd.
  • Klus Pharma Inc.
  • Henan Genuine Biotech Co., Ltd.
  • Gilead Sciences
  • Genentech, Inc.
  • Revolution Medicines, Inc.
  • Servier Bio-Innovation LLC
  • Summit Therapeutics
  • Chipscreen Biosciences, Ltd.
  • Eli Lilly and Company
  • Integro Theranostics
  • Amgen
  • Tango Therapeutics, Inc.
  • Verastem, Inc.
  • Nuvalent Inc.
  • ArriVent BioPharma, Inc.
  • IO Biotech
  • Betta Pharmaceuticals Co., Ltd.
  • Replimune, Inc.
  • ImmunityBio, Inc.

目錄

第1章：主要調查結果和分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

  • 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

  • 重點
  • 發病率/盛行率
  • 已確診並接受藥物治療的患者人數
  • 合併症
  • 其他相關患者群

第4章 市場規模及預測

  • 重點
  • 市場促進因素與限制因素
  • 按藥物類別分類的趨勢
  • 各國具體趨勢

第5章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 主要治療方法概述及KOL洞察
  • 新興治療方法
  • 重點
  • 值得關注的後期新治療方法－概述、市場上市預期及KOL洞察
  • 值得關注的早期管道

第6章：未滿足的需求與目標產品分析

  • 主要未滿足的需求及其未來透過新興治療方法實現的可能性
  • TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

簡介目錄

Global Non-Small Cell Lung Cancer Market Outlook

Thelansis's "Global Non-Small Cell Lung Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non-Small Cell Lung Cancer treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Non-Small Cell Lung Cancer Overview

Non-small cell lung cancer (NSCLC) is the most prevalent lung malignancy, encompassing adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, driven by diverse oncogenic alterations including EGFR mutations, ALK and ROS1 rearrangements, KRAS G12C mutations, MET exon 14 skipping, RET fusions, and BRAF V600E mutations alongside PD-L1 overexpression. Tobacco smoking remains the dominant risk factor, though never-smoker adenocarcinoma with targetable driver mutations represents a growing subpopulation. Patients present with persistent cough, haemoptysis, dyspnoea, and constitutional symptoms, with many diagnosed at advanced stages. Comprehensive next-generation sequencing and PD-L1 immunohistochemistry are mandatory at diagnosis. Pembrolizumab monotherapy is standard for high PD-L1 expressors, while chemoimmunotherapy addresses lower expressors. EGFR-mutated disease is addressed with osimertinib monotherapy or the amivantamab plus lazertinib combination, including a recently approved subcutaneous formulation, which has fundamentally redefined frontline standards by delivering superior progression-free survival over monotherapy. ALK is addressed with alectinib, ROS1 with entrectinib, KRAS G12C with adagrasib, MET with tepotinib, RET with selpercatinib, and BRAF V600E with dabrafenib-trametinib. Surgical resection remains curative for localised disease, with adjuvant osimertinib improving survival in resected EGFR-mutated NSCLC. Prognosis varies markedly with stage and molecular subtype; multidisciplinary management, smoking cessation, and patient-centred supportive care are integral to optimising outcomes.

Key Highlights

  • In Germany, survival-adjusted prevalent cases of Non-Small Cell Lung Cancer (NSCLC) are projected to increase from 497,473 patients in 2025 to 532,039 patients by 2035, reflecting improved survival outcomes and growing disease burden.
  • NSCLC remains the most common subtype of lung cancer, accounting for the majority of lung cancer diagnoses and mortality worldwide.
  • Increasing adoption of molecular diagnostics and biomarker testing is enabling broader use of precision oncology approaches in Germany.
  • Treatment paradigm has significantly shifted toward targeted therapies and immuno-oncology agents, improving progression-free and overall survival outcomes.
  • Persistent unmet need exists in resistant mutations, late-stage diagnosis, metastatic disease progression, and treatment sequencing optimization.
  • Growing focus on KRAS, EGFR, ALK, HER2, and PD-(L)1 targeted therapies is expected to further transform the competitive landscape over the forecast period.

Market Overview

  • The France NSCLC market is projected to grow from USD 1.3 billion in 2025 to USD 3.2 billion by 2035, indicating strong market expansion driven by innovation in oncology therapeutics.
  • Market growth is driven by:
  • Rising adoption of premium-priced targeted therapies and immunotherapies
  • Increasing biomarker-driven treatment eligibility and personalized medicine approaches
  • Improved survival rates leading to longer treatment duration
  • Market value is supported by continuous launch of next-generation oncology agents and expanding utilization of combination treatment regimens.
  • A robust pipeline of novel targeted therapies, antibody-drug conjugates (ADCs), and next-generation checkpoint inhibitors is expected to create significant commercial opportunities.
  • Future growth will depend on advancements in early detection, overcoming therapeutic resistance, and improving long-term survival in advanced and metastatic NSCLC patients.

Market Definition:

  • North America (United States, Canada)
  • Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
  • Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
  • Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
  • Africa (Egypt, Nigeria, South Africa, Morocco)
  • South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support
  • As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2025-2035)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market's trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

  • North America (United States, Canada)
  • Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
  • Middle Eas

Companies Mentioned

  • Pfizer
  • Merck Sharp & Dohme LLC
  • AstraZeneca
  • GlaxoSmithKline
  • BeiGene
  • Arcus Biosciences, Inc.
  • AbbVie
  • STCube, Inc.
  • Avistone Biotechnology Co., Ltd.
  • Regeneron Pharmaceuticals
  • Suzhou Zelgen Biopharmaceuticals Co., Ltd.
  • Daiichi Sankyo
  • Akeso
  • Bristol-Myers Squibb
  • RemeGen Co., Ltd.
  • BioNTech SE
  • Hoffmann-La Roche
  • Nuvation Bio Inc.
  • TJ Biopharma Co., Ltd.
  • Klus Pharma Inc.
  • Henan Genuine Biotech Co., Ltd.
  • Gilead Sciences
  • Genentech, Inc.
  • Revolution Medicines, Inc.
  • Servier Bio-Innovation LLC
  • Summit Therapeutics
  • Chipscreen Biosciences, Ltd.
  • Eli Lilly and Company
  • Integro Theranostics
  • Amgen
  • Tango Therapeutics, Inc.
  • Verastem, Inc.
  • Nuvalent Inc.
  • ArriVent BioPharma, Inc.
  • IO Biotech
  • Betta Pharmaceuticals Co., Ltd.
  • Replimune, Inc.
  • ImmunityBio, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)